References
- Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opinion on Pharmacotherapy. 2016;17: 761–781.
- Perez F, Bonomo RA. Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria. Lancet Infectious Diseases. 2018;18: 358–360.
- Abdallah M, Balshi A. First literature review of carbapenem-resistant Providencia. New Microbes New Infections. 2018;25: 16–23.
- Sharma D, Sharma P, Soni P. First case report of Providencia Rettgeri neonatal sepsis. BMC Research Notes. 2017;10: 536.
- Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, et al. Treatment of infections caused by multidrug-resistant Gram-negative bacteria: Report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party. Journal of Antimicrobial Chemotherapy. 2018;3: 73–78.
- Shin S, Jeong SH, Lee H, Hong JS, Park M-J, Song W. Emergence of multidrug-resistant Providencia rettgeri isolates co-producing NDM-1 carbapenemase and PER-1 extended-spectrum beta-lactamase causing a first outbreak in Korea. Annals of Clinical Microbiology and Antimicrobials. 2018;1: 17–20.
- Douka E, Perivolioti E, Kraniotaki E, Fountoulis K, Economidou F, Tsakris A, et al. Emergence of a pandrug-resistant VIM-1-producing Providencia stuartii clonal strain causing an outbreak in a Greek intensive care unit. International Journal of Antimicrobial Agents. 2015;45: 533–536.
- Zavascki AP, Carvalhaes CG, da Silva GL, Soares SFT, de Alcåntara LR, Elias LS, et al. Outbreak of carbapenem-resistant Providencia stuartii in an intensive care unit. Infection Control Hospital Epidemioogyl. 2012;33: 627–630.
- Makris D, Petinaki E, Tsolaki V, Manoulakas E, Mantzarlis K, Apostolopoulou O, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian Journal Critical Care Medicine. 2018;22: 67–77.
- Zalts R, Neuberger A, Hussein K, Raz-Pasteur A, Geffen Y, Mashiach T, et al. Treatment of carbapenem-resistant acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam. American Journalof Therapeutics. 2016;23: 78–85.
- Ranzani OT, Prina E, Torres A. Nosocomial pneumonia in the intensive care unit: how should treatment failure be predicted? Revista Brasileira de terapia intensiva. 2014;26: 208–211.
- Fisher K, Trupka T, Micek ST, Juang P, Kollef MH. A prospective one-year microbiologic survey of combined pneumonia and respiratory failure. Surgical Infections. 2017;18: 827–833.
- Sah R, Khadka S, Shrestha GS, Acharya S, Aryal D, Shrestha P, et al. Detection of Pan drug resistance OXA-48 producing Providencia in an ICU patient for the first time in Nepal. Antimicrobial Resistance & Infection Control. 2019;8: 155.
- Hara GL, Gould I, Endimiani A, Pardo PR, Daikos G, Hsueh PR, et al. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: Recommendations from an International Working Group. Journal of Chemotherapy. 2013;25: 129–140.
- Tshisevhe VS, Lekalakala MR, Tshuma N, van Rensburg SJ, Mbelle N. Outbreak of carbapenem-resistant Providencia rettgeri in a tertiary hospital. South African Medical Journal. 2017;107: 36–38.